Milton Boyer

Milton has served in technical, commercial, and executive roles in the pharmaceutical industry for more than 25 years, with a focus in contract manufacturing for both drug substance and sterile drug product. For the last 15 years, he has been immersed in the complexities of sterile drug product manufacturing, most recently as the chief executive officer of SCA Pharmaceuticals in Arkansas. He also was the head of drug product manufacturing for AMRI (now Curia), in New York, and chief executive officer of Oso BioPharmaceuticals, a sterile fill-finish contract manufacturer, when Altaris carved out Catalent’s site in New Mexico, to establish the business.

Active in trade groups and educational institutions supporting the pharmaceutical and biopharmaceutical industry, Milton has served on the board of directors and is the past president of the Drug, Chemical, & Allied Trades Association (DCAT). He has also served on the external advisory board for the University of New Mexico’s chemistry and biology department and been an active member of multiple professional organizations, including the American Association of Pharmaceutical Scientists, the Parenteral Drug Association, and the Society of Chemical Manufacturers and Affiliates.

Milton has a B.S. in chemistry/physics from Hardin-Simmons University and an M.S. in biochemistry from Texas Tech University.